PT886

Stay updated on biopharmaceutical advancements with the Synapse database, offering daily or weekly insights into drugs, targets, indications, and organizations.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received its second FDA Fast Track designation for treating neuroendocrine prostate cancer (NEPC). It also has orphan drug designations for small cell lung cancer and neuroendocrine carcinoma. PT217 is under evaluation in Phase I/II trials for advanced cancers expressing DLL3.

Courtney Van Houzen, PharmD, discusses bringing bispecific antibody treatments to community settings, inspired by a patient's need for continuity of care. Promising efficacy and safety of fianlimab and cemiplimab in advanced melanoma is highlighted. Inavolisib plus palbociclib and fulvestrant gains FDA approval for HR+/HER2- PIK3CA-mutated breast cancer. Talazoparib plus enzalutamide shows survival improvement in mCRPC. The TWINPEAK trial initiates with PT886 and pembrolizumab for gastric and GEJ cancers.

The TWINPEAK trial (NCT05482893) has dosed its first patient, evaluating PT886 combined with pembrolizumab for gastric and GEJ cancers. PT886 targets claudin 18.2 and CD47 to enhance immune response. The study is a multicenter, open-label, phase 1/2 trial assessing safety, tolerability, and efficacy in advanced gastric, GEJ, and pancreatic cancers. PT886 has FDA orphan drug designation for pancreatic cancer and fast track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma.

Phanes Therapeutics announced the first patient dosed in the PT886 clinical study combined with Merck's KEYTRUDA® for gastric and gastroesophageal junction cancers. PT886, a first-in-class bispecific antibody, targets claudin 18.2 and CD47, and is being evaluated in various cancer treatments.

First patient dosed in Phanes Therapeutics' clinical study of PT886 combined with Merck's KEYTRUDA for gastric and gastroesophageal junction cancers. PT886, a first-in-class bispecific antibody, targets claudin 18.2 and CD47, and is also being evaluated in pancreatic cancers.

Phanes Therapeutics announced the first patient dosed in PT886 clinical study, a bispecific antibody targeting claudin 18.2 and CD47, in combination with chemotherapy for pancreatic and gastric cancers. The TWINPEAK study evaluates PT886's safety and efficacy in advanced or metastatic cases. PT886 has FDA orphan drug and Fast Track designations.

The FDA granted fast track designation to PT217 for treating ES-SCLC post-platinum-based chemotherapy. PT217, a bispecific antibody targeting DLL3 and CD47, is in phase 1 trials for SCLC, LC-NEC, and EP-NEC, aiming to enhance antitumor activity through immune system activation. The SKYBRIDGE trial evaluates its safety and efficacy in advanced refractory cancers.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC). PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates in these aggressive cancers.